Regen BioPharma Inc. (RGBPP) intrinsic value & 10-year financials
Regen BioPharma Inc. (RGBPP) has a Graham intrinsic value of $1.02 per share. Over the last 10 fiscal years revenue grew 10.0% a year to $236.6K, with an average return on invested capital of 278.6%.
- Graham intrinsic value
- $1.02
- Revenue (FY2025)
- $236.6K
- Revenue growth (10-yr CAGR)
- 10.0%
- ROIC (10-yr avg)
- 278.6%
- Free cash flow (FY2025)
- —
RGBPP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $236.6K | -$1.3M | -$0.05 | — | -143.1% | 5.9% |
| FY2024 | $236.6K | -$668.3K | -$0.03 | — | -176.4% | 8.1% |
| FY2023 | $236.6K | $1.2M | $0.05 | — | -290.4% | -17.6% |
| FY2022 | $125.5K | $2.4M | $0.12 | — | -270.6% | -22.7% |
| FY2021 | $61.2K | -$6.8M | — | — | -328.1% | 65.0% |
| FY2020 | $110.0K | $3.4M | — | — | -190.3% | -37.4% |
| FY2019 | $110.0K | -$2.6M | — | — | -688.0% | 26.2% |
| FY2018 | $100.0K | -$4.7M | — | — | -1425.8% | 65.6% |
| FY2017 | $110.0K | -$5.8M | — | — | -2282.6% | 1157.0% |
| FY2016 | $100.0K | -$7.8M | — | — | -2957.0% | 1535.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Regen BioPharma Inc is a consistent compounder, expanding top-line revenue at 10.0% annually over the past decade.
Regen BioPharma Inc returns on capital have been average, hovering around 12.0% ROIC over the decade.
Regen BioPharma Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Regen BioPharma Inc is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.02 per share.